Kura Oncology (NASDAQ:KURA – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $30.00 target price on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 172.73% from the […]
Related Keywords
United States , Stifel Nicolaus , Thomas Malley , Suvretta Capital Management , Kura Oncology Company Profile , Vanguard Group Inc , Securities Exchange Commission , Cantor Fitzgerald , Kura Oncology Inc , Blackrock Inc , Kura Oncology , Get Free Report , Oncology Stock Down , Director Thomas Malley , Exchange Commission , Capital Management , Street Corp , Vanguard Group , Lysinek Specific Methyltransferase , Kura Oncology Daily , Nasdaq Kura , Kura , Medical , Reiterated Rating ,
comparemela.com © 2020. All Rights Reserved.